An observational study in Multimorbidity, sponsored by Gerencia de Atención Primaria, Madrid. Enrolling by invitation at 1 site in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Gerencia de Atención Primaria, Madrid · Observational
The overall objective of the study is to analyze the evolution of multimorbidity, its most relevant patterns and trajectories in the Spanish National Health System population, from 2012 to 2022, and to analyze the factors that determine it, as well as the experience of professionals and patients in navigating the health system and in shared decision making.
Multimorbidity trajectories can help identify homogeneous groups of individuals with similar needs and prognoses, and help practitioners and health systems to personalize clinical interventions and preventive strategies. Capturing this dynamism is the only way to better understand the natural history of multimorbidity and shed light on hitherto unexplained findings.
Design: Mixed-method study.
Analysis:
Gerencia de Atención Primaria, Madrid is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patientes aged 60 years or older with 2 or more chronic diseases diagnosed before 2012-01-01. Population registered at Primary Health Centres in Spain.
Sampling Method: Not Applicable
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
- Not having used the national health system in the last year
Ambispective longitudinal observational study
Other: Retrospective and prospective cohort
Focus group, semi-structured interviews and Photovoice
Other: Focus group, semi-structured interviews and Photovoice
Systematic literature review on the effectiveness of interventions on training, multimorbidity and polypharmacy in health professionals.
Other: Systematic review
* Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded. * Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia.
The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.
No patient recruitment required
Multimorbidity
Presence of two or more diagnoses of any of the 60 diseases categorised by the Swedish National Study of Ageing and Care (SNAC-K20) (It is a classification, not a scale)
Time frame: Baseline
Death
Death and abandonment: the occurrence of this event will be measured, regardless of the cause
Time frame: Start date 31/12/2012, 1 year
Drugs
300 ATC Swedish National Study of Ageing and Care (SNAC-K20) 8It is a classification, not a scale)
Time frame: 1 year
Use of service
Primary Care medical/nursing visits, emergencies, referrals, admissions
Time frame: 1 year
Morbidity
Defined with ICD-10, laboratory defined in the Swedish National Study of Ageing and Care (SNAC-K20). It is a classification, not a scale
Time frame: Baseline/ 1 year
Frailty
EFRAIL (It consists of 5 dichotomous questions. Scoring from 0 to 5. Interpretation: * Probable frailty: 3 to 5 points. * Probable pre-fragility: 1 to 2 points. * No fragility or robustness: 0 points)
Time frame: Baseline/ 1 year
Adherence
Morisky-Green (Patients who answer NO to all four questions are considered compliant with treatment and those who answer YES to one or more are considered non-compliant)
Time frame: Baseline
Social support
Dukes-Unk-11(This questionnaire consists of 11 items and a Likert-type response scale. The score range is between 11 and 55 points. A score equal to or greater than 32 indicates normal support, while a score of less than 32 indicates low perceived social support)
Time frame: Baseline
Functioning and disability
WHODAS (It is composed of 36 items that evaluate the following 6 dimensions. The overall score runs a scale from 0 to 100, with higher values indicating greater disability)
Time frame: Baseline/ 1 year
Health releated quality of life
Euroqol 5D-5L (It consists of 2 parts - The EQ-5D descriptive system and the Visual Analog Scale (VAS). Scale (VAS). In the VAS the individual scores his or her health between two extremes, 0 and 100, the worst and the best state of health imaginable. imaginable)
Time frame: Baseline
Age
Years
Time frame: Baseline
Sex
Male/Female
Time frame: Baseline
Country
Country of origin
Time frame: Baseline
Deprivation Index
MEDEA (Values from 1 to 5. Higher values indicate a more unfavorable socioeconomic situation)
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for Jul 2025, 12 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gerencia de Atención Primaria, Madrid